# Maraviroc as GVHD Prophylaxis in Transplant Recipients

> **NCT02167451** · PHASE1,PHASE2 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 31 (actual)

## Conditions studied

- Diagnoses That Require Stem Cell Transplant
- Graft Versus Host Disease (GVHD)

## Interventions

- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT02167451
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** slow recruitment and no further drug supply
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167451, "Maraviroc as GVHD Prophylaxis in Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02167451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*